LncRNAs as Potential Therapeutic Targets in Thyroid Cancer
- PMID: 32102500
- PMCID: PMC7332117
- DOI: 10.31557/APJCP.2020.21.2.281
LncRNAs as Potential Therapeutic Targets in Thyroid Cancer
Abstract
Thyroid cancer (TC) is the most common cancer of endocrine system. TC can be subdivided into 4 different entities, papillary, follicular, medullary and anaplastic thyroid cancer. Among them, anaplastic thyroid cancer has the poorest prognosis. Exploring new therapeutic approach may entail favorable prediction as well as increasing overall survival rate of patients. Long non-coding RNAs (lncRNAs), have vast implications in different cancer types. Although they are not transcribed into proteins, they can act as a harness in regulating a plethora of biological functions. They have been implicated in a decisive role in gene expression via modulation of both coding and non-coding RNAs. This article discuss the multi-facet role of lncRNA in thyroid cancer biology.<br />.
Keywords: Diagnosis; Thyroid cancer; genetic alterations; lncRNA; treatment.
Figures
References
-
- Bhan A, Mosella M, Singer MC, et al. DNA methylation signature associated with risk of recurrence in papillary thyroid carcinoma. Thyroid. 2018;28:A24.
-
- Chu R, Van Hasselt A, Vlantis AC, et al. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer. 2014;120:142–53. - PubMed
-
- Covach A, Patel S, Hardin H, et al. Phosphorylated Mechanistic target of Rapamycin (p-mTOR) and Noncoding RNA expression in follicular and Hürthle cell thyroid neoplasm. Endocr Pathol. 2017;28:207–12. - PubMed
